Drug Maker Pfizer Quietly Issues Recall of Popular Drug Lyrica

Comments (0)

The huge drug company Pfizer has quietly recalled three lots of its popular prescription drug Lyrica. The recall only involves 50 and 75 mg capsules with a certain lot number and expiration date. 

According to the company, exposure to those batches of Lyrica is not expected to cause health problems. Pfizer only sent notices of the recall to retailers that may have received a shipment of the pills. Pfizer did not publicize the recall, notify patients, issue press releases, or announce the information on its website. 

The company says that some capsules in the affected lots were damaged. Those pills could have lost some of their active ingredient, meaning that the patient may not be receiving the correct dosage, so the prescription may not be as effective as it would be otherwise. 

Lyrica was originally developed as a way to help treat epileptic seizures. Since then, it has also been approved to treat diabetic nerve pain, fibromyalgia, neuralgia caused by shingles and spinal cord injury, as well as lower back pain. Lyrica is Pfizer's best-selling drug and generates over $5 billion in sales annually. It has been approved for use in more than 130 countries. 

Drug companies make billions a year in sales of prescription drugs, yet when their drugs are found to have harmed patients, they send teams of attorneys to fight the injured individuals. Those who are injured by dangerous prescription drugs have the legal right to compensation. If you have been injured, call the Houston personal injury attorneys at Kennedy Hodges at 855-947-0707, or visit our LinkedIn page. We will be happy to provide you with a free consultation on your case. Call today to learn more. Description: https://ssl.gstatic.com/ui/v1/icons/mail/images/cleardot.gif

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Message:*

Notify me of follow-up comments via email.